智飞生物(300122.SZ)：CA111注射液获药物临床试验批准

Core Viewpoint - The announcement highlights that Zhifei Biological's subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults [1] Group 1: Product Development - CA111 injection is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors [1] - GIP is a 42-amino acid gastrointestinal regulatory peptide that stimulates insulin secretion from pancreatic beta cells in the presence of glucose and protects these cells, playing a physiological role in glucose homeostasis [1] - GLP-1 is a 37-amino acid peptide that stimulates insulin secretion, protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying, and food intake, thereby controlling blood sugar and body weight [1] - The dual receptor agonist mechanism of GIP and GLP-1 can achieve synergistic effects for better glucose-lowering and weight loss outcomes [1]